Blue-Chip Stocks: The 10 Long-Term Holdings That Built Portfolios

The term comes from poker: the blue chips are the most valuable ones on the table. In markets, a blue-chip stock is a large, financially sound company with a long record of surviving recessions, scandals, wars and technology shifts - and coming out compounding.

That is the definition. The useful question is what it excludes, and what happens when a company stops deserving the label.

The three tests

All three are checkable from a company's own annual report, filed publicly and searchable free through the SEC's EDGAR database.

Before any stock earns "hold it for a decade" status, it should pass:

1. The moat test. Does something structural protect its profits - a brand (Coca-Cola), a network (Visa), an ecosystem (Apple), scale (Walmart)? If a competitor with unlimited money would still struggle to displace it in five years, that is a moat.
2. The balance-sheet test. Investment-grade credit, manageable debt, real free cash flow. Blue chips get cheaper access to capital in a crisis, which is exactly when they buy their weakened competitors.
3. The boredom test. The business should make money in ways so predictable they are dull. Excitement is what you pay for; boredom is what pays you.

Notice that none of the three is "the share price went up a lot." Price performance is the output. These are the inputs.

The classic ten

Our live table tracks current prices and ten-year returns for the canonical list: Apple, Microsoft, JPMorgan Chase, Johnson & Johnson, Coca-Cola, Procter & Gamble, Visa, Walmart, ExxonMobil and Home Depot.

Notice what that list is: two technology platforms, a bank, healthcare, two consumer staples, a payments network, a retailer, an energy major and a home-improvement chain. The spread is not an accident. It is a diversified economy in ten tickers.

What the ten-year numbers teach

Look at the live table and three lessons jump out:

• The dispersion is enormous. Even among "safe" blue chips, the best ten-year performer can return five to ten times the weakest. Safe does not mean equal, and it certainly does not mean interchangeable.
• Boring beats exciting more often than you would think. Walmart - a grocery store - outperformed most of the market from 2023 onward.
• Even blue chips go sideways for years. Johnson & Johnson and Procter & Gamble have both had long flat stretches. The dividend is what pays you to wait through them.

The part most articles skip: blue chips fail

This is consistent with the broader evidence on stock selection: S&P's SPIVA scorecard finds most professional managers trailing their benchmark over a decade, and picking famous companies is a blunter instrument than what those managers are doing.

The label is a description of the present, not a guarantee about the future, and the history of "safe" large caps is littered with companies that stopped qualifying while investors kept holding them out of habit.

General Electric was for decades the archetypal widows-and-orphans holding - a Dow component, a dividend payer, an American institution. Its shareholders were nonetheless devastated over the 2000s and 2010s as its finance arm unravelled and the conglomerate was eventually broken apart.

IBM spent much of the 2010s shrinking while paying a dividend, an arrangement that looks like income and functions like slow erosion.

General Motors entered bankruptcy in 2009 and its common shareholders were wiped out. It had been a blue chip for most of a century.

The lesson is not that blue chips are dangerous. It is that the three tests above are not a one-time assessment. A moat can erode. A balance sheet can deteriorate. The boredom test can be failed by a management team that decides to become exciting.

How to actually hold them

Three practical points that matter more than stock selection:

Diversify across the group, not into one name. Ten blue chips across eight sectors behaves very differently from your three favourites. If you cannot be bothered with ten positions, an index fund owns all of them and several hundred more - see our comparison of index funds.

Reinvest the dividends automatically. Most of the long-run return from consumer staples and healthcare in particular has come from reinvested income, not price appreciation. Taking dividends as cash quietly converts a compounding machine into a modest income stream.

Rebalance rarely, but do rebalance. Left alone for a decade, a ten-stock portfolio will typically become a two-stock portfolio plus eight rounding errors, because winners compound. That may be fine - but it should be a decision, not an accident.

The realistic strategy

Buy steadily, reinvest dividends, and let a decade pass. Re-run the three tests once a year - it takes an evening - and be willing to conclude that something on your list no longer passes. That is the whole method.

What it is not is a shortcut. Blue chips are the slow, unglamorous path, and their advantage is precisely that most people abandon it in year three for something more interesting.

Not investment advice. Past performance does not guarantee future results. Company examples are historical illustrations, not recommendations.